XenoGesis Ltd. is an independent laboratory-based contract research organisation (CRO) specialised in preclinical drug metabolism & pharmacokinetics (DMPK), quantitative bioanalysis and expert interpretation.
They also work in areas such as Human PK and Dose Prediction.
Understanding of metabolism, PK/PD relationships and prediction of efficacious human exposure and dose are critical success factors for any Discovery project. The combined pharmacology and DMPK expertise of TherapeutAix and Xenogesis ensures that our clients have access to the best capabilities and advice in this respect as the foundation of a strong translational story.
“XenoGesis is very pleased to recommend TherapeutAix. We have worked closely with the founders of TherapeutAix over the last 4 years to advance drug discovery projects. Their extensive knowledge and skills across multiple therapeutic areas and in pharmacology, translational drug discovery and early clinical development, coupled with an effective and focused approach to review and decision-making, has allowed our clients to refine and position projects for success. We believe that XenoGesis and TherapeutAix working together can address key risks in PK/PD and offer our clients a seamless, cost and time-efficient route to success for their drug discovery and development programmes. The team at TherapeutAix fully understand that success is defined as survival at the next stage of R&D with the clinical goal in sight.”
– Richard Weaver, Founder and CEO, XenoGesis Ltd